

Specimen Collected: 06-Nov-25 13:44

von Willebrand Factor Panel with Reflex	Received: 06-Nov-25 13:44	Report/Verified: 10-Nov-25 12:28
---	---------------------------	----------------------------------

Procedure	Result	Units	Reference Interval
Factor VIII, Activity	42 ^L ⁱ¹	%	[56-191]
von Willebrand Factor, Activity (GPIbM)	70 ^{f1} ⁱ²	%	[51-215]
von Willebrand Factor, Antigen	51 ^L ⁱ³	%	[52-214]
VWF:GPIbM /vWF Antigen Ratio	1.4	ratio	[>=0.7]

von Willebrand Factor Multimers	Received: 06-Nov-25 13:44	Report/Verified: 10-Nov-25 12:32
---------------------------------	---------------------------	----------------------------------

Procedure	Result	Units	Reference Interval
von Willebrand Factor Multimers	See Note ^{f2} ⁱ⁴		

Result Footnote

f1: von Willebrand Factor, Activity (GPIbM)

von Willebrand Factor Multimers added.

f2: von Willebrand Factor Multimers

von Willebrand factor multimeric analysis shows a normal multimeric distribution. The von Willebrand panel results are abnormal with one or more low values. However, current guidelines (Blood Adv. 2021; 5(1):280-300. and Haemophilia 2008;14:171-232) suggest that only values less than 30% of normal support a definite diagnosis of von Willebrand disease. Low values that are >30% of normal may indicate von Willebrand disease if there is supporting clinical and/or family evidence. Repeat testing may be necessary for diagnosis in some cases. Additional information regarding diagnosis and subtyping of von Willebrand disease is available at arupconsult.com.

von Willebrand factor and factor VIII are acute phase reactants. Increased values are seen in pregnancy, with estrogen-containing medications, inflammation, infection, liver disease, malignancy, and with exercise, stress, or trauma, including traumatic venipuncture. Acute phase reactions can mask low baseline values in patients with von Willebrand disease.

Lower baseline von Willebrand and factor VIII values are found in blood type O individuals. Decreased values for von Willebrand factor and/or factor VIII activity may also be due to improper specimen handling.

Test Information

i1: Factor VIII, Activity

REFERENCE INTERVAL: Factor VIII, Activity

Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com).

i2: von Willebrand Factor, Activity (GPIbM)

INTERPRETIVE INFORMATION: von Willebrand Factor Activity,
GPIbM

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i3: von Willebrand Factor, Antigen

REFERENCE INTERVAL: von Willebrand Factor, Antigen

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 25-310-900149**Report Request ID:** 20897706**Printed:** 10-Nov-25 13:03

Page 1 of 2

Patient Age/Sex: 37 years Male

Test Information

i3: von Willebrand Factor, Antigen

Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com).

i4: von Willebrand Factor Multimers

INTERPRETIVE INFORMATION: von Willebrand Factor Multimers

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 25-310-900149**Report Request ID:** 20897706**Printed:** 10-Nov-25 13:03

Page 2 of 2